Nephrology
| IgA nephropathy
Nephrology
IgA nephropathy
PROTECT: Patient-reported outcomes with sparsentan and irbesartan in IgAN
book_2
Source:
Kidney Week 2024. Poster Session.
calendar_today
Published on Medfyle:
November 2024
In this medfyle
Patient-reported outcomes are important to understand whether clinical efficacy translates into improvements in patients’ health-related quality of life. New data from PROTECT suggest sparsentan reduces the burden of kidney disease over time.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
©2024 Infomedica-Medfyle. All rights reserved.
Source: Patient-Reported Outcomes in the PROTECT Clinical Trial Comparing Sparsentan with Irbesartan for IgA Nephropathy. Wadhwani S, et al. Presented at Kidney Week 2024; #FR-PO868.
The information and data provided is for information purposes only. The author(s) of the original original presentation had no involvement in the creation of this content.
